…read more Source: Valeant bids $296M on Dendreon; AstraZeneca pairs with MD Anderson;
Cancer drug developer Tracon Pharmaceuticals pulled in $36 million in an IPO, pricing well below its expected range as it works to get its top drug into late-stage trials. …read more Source: Tracon raises $36M in a downsized IPO
President Barack Obama is asking Congress for $215 million to sequence the genomes of 1 million Americans and help develop a new generation of medicines, part of a sweeping plan to accelerate biomedical R&D. …read more Source: Obama wants $215M to kick off ‘precision medicine’ project
Pfizer is walking away from a $70 million collaboration with Waltham, MA’s Repligen, handing back some early-stage treatments for the rare spinal muscular atrophy. …read more Source: Pfizer bails on a $70M rare disease deal with Repligen
…read more Source: Alexion names David Hallal its next CEO
Intercept Pharmaceuticals has nabbed the FDA’s breakthrough drug designation for obeticholic acid, a closely watched therapy in the pipeline for a blockbuster NASH indication. …read more Source: Intercept nabs a ‘breakthrough’ title for its blockbuster NASH contender
In this week’s EuroBiotech Report, Belgian biotech ThromboGenics, having seen its stock price peak at €45 two years ago, has experienced a series of share slides, the latest of which was triggered by its partner Novartis. And more. …read more Source: Novartis pins weak Jetrea sales on PhIII, KDEV CEO leaves after 3 months, Cantargia […]
When you want to develop a drug for, say, cancer, objective measures such as survival rate can tell regulators just how effective it is compared to a standard drug or placebo. But in diseases involving the brain, scientists often have to settle for crude measures for assessing how patients perform or feel after treatment. And […]
President Barack Obama’s plot to bolster personalized medicine research would lean heavily on a planned bank of patient genetic information, Science magazine reports, pooling existing databases to create a huge R&D utility. But the promise of a so-called Precision Medicine Initiative has left some scientists cold, hearkening back to overblown efforts past. …read more Source: […]
Biogen Idec and its newly named in-house expert Olivier Danos have executed a research deal with the San Raffaele-Telethon Institute for Gene Therapy to develop what they believe promises to be a durable treatment for hemophilia. …read more Source: Biogen Idec quietly carves out a leading role in developing gene therapy for hemophilia
